Publications by authors named "Song Luxi"

Claim this Profile
A
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study.
Minghua Hong, Dawei Ding, Min Zhang, Sujun Gao, Luxi Song

Eur J Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of somatic mutations and additional chromosomal abnormalities in patients with myelodysplastic syndromes and chromosome 20q deletion.
Xinhui Huang, Xiao Li, Qi Liu, Juan Guo, Jianan Chen, Luxi Song

Clin Exp Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation.
Qi Liu, Fanhuan Xu, Juan Guo, Feng Xu, Xinhui Huang, Luxi Song

Cancer Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes.
Minghua Hong, Juan Guo, Youshan Zhao, Luxi Song, Sida Zhao

Eur J Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.
Fanhuan Xu, Jiacheng Jin, Juan Guo, Feng Xu, Jianan Chen, Luxi Song

J Cancer Res Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
deficiency impairs HSPC homeostasis and erythropoiesis via and predicts poor prognosis in MDS.
Jia-Cheng Jin, Bing-Yi Chen, Chu-Han Deng, Jia-Nan Chen, Feng Xu

Sci Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression.
Roujia Wang, Youshan Zhao, Zijuan Li, Juan Guo, Sida Zhao, Luxi Song

Acta Biochim Biophys Sin (Shanghai)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of carbon monoxide breath test to detect the effect of iron overload on erythrocyte lifespan in MDS.
Yao Zhang, Yan Qian, Lu-Xi Song, Chao Xiao, Chun-Kang Chang

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome.
Youshan Zhao, Juan Guo, Sida Zhao, Roujia Wang, Lei Shi, Luxi Song

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the influencing factors related to liver and cardiac iron overload in MDS patients detected by MRI in the real world.
Chao Xiao, Yao Zhang, Jun-Gong Zhao, Lu-Xi Song, You-Shan Zhao

Hematology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated traditional Chinese and conventional medicine in the treatment of anemia due to lower-risk myelodysplastic syndrome: study protocol for a randomized placebo-controlled trial.
Qin Zheng, Haitao Xu, Luxi Song, Zeying Yan, Manqin Sun

Trials· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Xiao Li, Feng Xu, Zheng Zhang, Juan Guo, Qi He

Clin Epigenetics· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Study on Iron Content Detection by Energy Spectral CT and MRI in MDS Patients.
Yao Zhang, Chao Xiao, Jing Li, Lu-Xi Song, You-Shan Zhao

Front Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration Analysis of or Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome.
Ying Fang, Juan Guo, Dong Wu, Ling-Yun Wu, Lu-Xi Song

Front Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation.
Zheng Zhang, Yan Jia, Feng Xv, Lu-Xi Song, Lei Shi

Front Genet· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy.
Lingyun Wu, Xiao Li, Feng Xu, Dong Wu, Qi He, Luxi Song

Br J Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Cai Xiu, Xiao Li, Lingyun Wu, Feng Xu, Qi He, Luxi Song

J Cancer Res Clin Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome.
Qing-Qing Zheng, You-Shan Zhao, Juan Guo, Si-da Zhao, Lu-Xi Song

Leuk Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Zheng Zhang, Chun-Kang Chang, Qi He, Juan Guo, Ying Tao

Leuk Lymphoma· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Chun-Kang Chang, You-Shan Zhao, Feng Xu, Juan Guo, Zheng Zhang

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes.
Feng Xu, Ling-Yun Wu, Qi He, Dong Wu, Zheng Zhang

Sci Rep· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.
Zheng Zhang, Qi He, Ying Tao, Juan Guo, Feng Xu

Am J Transl Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Lingyun Wu, Wenhui Shi, Xiao Li, Chunkang Chang, Feng Xu, Luxi Song

J Transl Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[MRI for assessment of iron overload in patients with hematologic disease].
Chao Xiao, Shucheng Gu, Yanjun Xu, Zhuo Chen, Luxi Song

Zhonghua Xue Ye Xue Za Zhi· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes.
Feng Xu, Ling-Yun Wu, Chun-Kang Chang, Qi He, Zheng Zhang

Nat Commun· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis